Results 251 to 260 of about 1,060,485 (284)

Complement Inhibitors Targeting C3, C4, and C5

2000
Activation of the complement system (Fig. 1) is the key to the development of normal inflammatory responses against foreign pathogens. During the course of this activation process a number of biological events are initiated, including generation of small peptides that induce local inflammatory responses, tagging of foreign pathogens with complement ...
Arvind Sahu, Dimitrios Morikis, John D. Lambris   +2 more
openaire   +1 more source

Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies

Lupus, 2014
Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis.
Z, Romay-Penabad, A L, Carrera Marin, R, Willis, W, Weston-Davies, S, Machin, H, Cohen, A, Brasier, E B, Gonzalez   +7 more
openaire   +2 more sources

Pexelizumab – a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass

Expert Opinion on Biological Therapy, 2005
Myocardial injury and dysfunction in acute infarction and during cardiac surgery with cardiopulmonary bypass (CPB) are associated with an undesirable systemic inflammatory response, in which the complement cascade plays a major role. In animal models C5 inhibition has been found to significantly reduce myocardial infarct size and decrease cellular ...
Ani J, Fleisig, Edward D, Verrier
openaire   +2 more sources

Complement-Mediated Thrombotic Microangiopathy after Kidney Transplant: Should Treatment with C5 Inhibitor Be Lifelong?

Nephron
Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosuppressive medications. The optimal management and duration of treatment with C5 inhibitors (C5i) for CM-TMA in this patient population remain areas of ...
Pilar Musalem, Cristian Pedreros-Rosales, Hans Müller-Ortiz, Carlos Gutierrez-Navarro, J. Daniel Carpio   +4 more
openaire   +2 more sources

Complement levels in cigarette smokers: elevation of serum concentrations of C5, C9, and C1-inhibitor.

Journal of clinical & laboratory immunology, 1981
Serum levels of 13 individual complement component and control proteins were measured in 25 male cigarette smokers and 25 male non-smokers. A significant elevation of the mean serum levels of C5, C9 and C1-inhibitor was demonstrated for the smokers while levels of C1q, C2, C4, C3, C6, C8, Factor B, properdin, C3b inactivator and beta 1H did not differ ...
R J, Wyatt, R B, Bridges, D G, Halatek
openaire   +1 more source

Pozelimab/cemdisiran. Complement protein C5 inhibitor, Treatment of complement-mediated diseases

Drugs of the Future, 2023
openaire   +1 more source

Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471)

Current Medicinal Chemistry, 2020
Steven D Podos
exaly  

Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD

Medicom Conference Report MSMilan 2023, 2023
openaire   +1 more source

An inhibitor of complement C5 provides structural insights into activation

Proceedings of the National Academy of Sciences of the United States of America, 2020
Martin Parnov Reichhardt, Justin Deme, Susan Lea   +2 more
exaly  

CLINICAL DEVELOPMENT OF THE C5 COMPLEMENT INHIBITOR, PEXELIZUMAB

Shock, 2004
openaire   +1 more source